ArticleActa neurologica Belgica2025
The comparative analysis between sporadic and genetic Creutzfeldt-Jakob disease in China.
Article in Acta neurologica Belgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesCreutzfeldt-Jakob disease (CJD) is a transmissible neurodegenerative disorder with a fatal outcome. The present study investigated the difference on demographic, clinical and laboratory data between the patients with sporadic CJD (sCJD) and genetic CJD (gCJD).
methodsThirty-eight patients with CJD were enrolled in this study, including 28 patients with sCJD and 10 patients with gCJD. All patients were administered cognitive tests, brain magnetic resonance imaging (MRI), electroencephalogram (EEG), cerebrospinal fluid (CSF) 14-3-3 protein.
resultsThe patients with sCJD had similar onset age, mean death and survival time to the patients with gCJD. There were slightly more males in the patients with sCJD than in the patients with gCJD (p = 0.095). The percentages of onset symptoms were similar between sCJD and gCJD groups. Patients with sCJD had more parkinsonism than patients with gCJD on neurological examinations (p = 0.037). The patients with gCJD also had slightly more disinhibitation than the patients with sCJD (p = 0.090). There were similar abnormalities percentages on MRI, EEG, and CSF 14-3-3 protein. The gCJD patients had more widespread cortex abnormalities involving the frontal, temporal, parietal and occipital lobe, compared with the sCJD patients (p = 0.012).
conclusionThe patients with sCJD had similar epidemiological and clinical characteristics to the patients with gCJD, except more parkinsonism signs and less widespread cortex abnormalities on MRI.
Indexed as
Identifiers
39673584What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.